Estados financieros detallados de Annovis Bio, Inc. (ANVS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.04, ANVS presenta beneficios negativos (P/E no significativo) y un ROE del -6.86%. La capitalización bursátil es de $44M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $273370 | $111608 | $776256 | $3.1M | $8.5M | $16.5M | $38.8M | $20.0M | $25.2M |
| Generales y Administrativos | $409063 | $602329 | $829366 | $3.6M | $6.1M | $9.0M | $6.2M | $6.7M | $4.5M |
| Gastos Operativos | $682433 | $713937 | $1.6M | $6.6M | $14.5M | $25.5M | $45.0M | $26.7M | $29.7M |
| Beneficio Operativo | -$682000 | -$714000 | -$1.6M | -$6.6M | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M |
| EBITDA | $84 | $66 | -$791000 | 0 | -$14.5M | -$25.3M | -$56.2M | -$22.7M | -$28.9M |
| Gastos por Intereses | $84 | $66 | 0 | $47.2M | 0 | 0 | 0 | $1.9M | 0 |
| Beneficio Antes de Impuestos | -$682000 | -$714000 | -$991000 | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Impuestos | 0 | -$132 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$682000 | -$714000 | -$991000 | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| BPA | $-0.10 | $-0.10 | $-0.14 | $-0.87 | $-1.90 | $-3.10 | $-6.23 | $-2.02 | $-1.40 |
| BPA Diluido | $-0.10 | $-0.10 | $-0.14 | $-0.87 | $-1.90 | $-3.10 | $-6.23 | $-2.31 | $-1.40 |
| Acciones en Circulación (Diluidas) | $6.8M | $6.8M | $6.8M | $6.3M | $7.6M | $8.2M | $9.0M | $12.2M | $20.6M |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $347472 | $35312 | $1858 | $8.1M | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | $735075 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | -$745.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $357963 | $50992 | $747512 | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $357963 | $50992 | $1.1M | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Cuentas por Pagar | $71107 | $68425 | $1.2M | $341856 | $688074 | $4.0M | $1.3M | $2.3M | $2.6M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $490220 | $567943 | $2.0M | $578380 | $1.5M | $7.7M | $4.3M | $3.9M | $3.6M |
| Deuda a Largo | 0 | 0 | $499807 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $7.3M | $7.6M | $9.7M | $578380 | $1.5M | $7.7M | $18.0M | $4.6M | $4.2M |
| Reservas | -$7.1M | -$7.8M | -$8.8M | -$14.2M | -$28.7M | -$54.1M | -$110.3M | -$134.8M | -$163.7M |
| Patrimonio Neto | -$7.0M | -$7.6M | -$8.6M | $7.5M | $44.5M | $28.3M | -$7.8M | $9.3M | $16.9M |
| Deuda Total | 0 | 0 | $499807 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | -$347472 | -$35312 | $497949 | -$8.1M | -$45.7M | -$28.4M | -$5.8M | -$10.6M | -$19.5M |
| Capital Circulante | -$132257 | -$516951 | -$1.3M | $7.5M | $44.5M | $28.3M | $5.9M | $10.0M | $17.4M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$682349 | -$713871 | -$990980 | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Amortizaciones | 0 | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $48495 | $82728 | $8483 | $1.9M | $4.7M | $9.2M | $4.6M | $3.8M | $1.8M |
| Cambio en Capital Circulante | $96373 | $72534 | $421526 | -$400714 | $657346 | -$1.1M | -$228597 | $681705 | $1.6M |
| Flujo de Caja Operativo | -$537481 | -$558609 | -$476542 | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M |
| Inversiones (CapEx) | 0 | 0 | 0 | $3 | 0 | 0 | 0 | 0 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$537481 | -$558609 | -$476542 | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -4.7% | -38.8% | -451.2% | -165.2% | -74.8% | -121.9% | +56.2% | -17.3% | |
| Crecimiento BPA (anual) | +0.0% | -40.0% | -521.4% | -118.4% | -63.2% | -101.0% | +67.6% | +30.7% | |
| Cambio en Acciones (anual) | +0.0% | +0.4% | -7.8% | +20.9% | +7.0% | +10.5% | +35.6% | +68.0% | |
| Crecimiento FCF (anual) | -3.9% | +14.7% | -733.3% | -130.0% | -89.6% | -130.9% | +45.2% | -17.0% | |
| Tasa Impositiva Efectiva | -0.0% | 0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.08 | $-0.08 | $-0.07 | $-0.63 | $-1.20 | $-2.12 | $-4.43 | $-1.79 | $-1.25 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $6.8M | $6.8M | $6.8M | $6.3M | $7.6M | $8.2M | $9.0M | $12.2M | $20.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -685.96% |
| Rentabilidad sobre capital invertido | -400.40% |
| Rentabilidad sobre activos | -224.73% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 2.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.44 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| P/E | -95.90 | -95.90 | -68.50 | -8.67 | -9.25 | -4.33 | -3.00 | -2.49 | -2.47 |
| P/VC | -9.39 | -8.61 | -7.65 | 6.31 | 3.01 | 3.87 | -21.77 | 6.58 | 4.22 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explorar sector: Healthcare · Biotechnology
Más secciones de ANVS: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones